(142 days)
Not Found
No
The document explicitly states "Not Found" for mentions of AI, DNN, or ML, and the described features are limited to real-time B-mode ultrasound imaging and image post-processing techniques (BoneEnhance®, SpineNav3D™) which are not inherently AI/ML.
No
The device is intended for diagnostic ultrasound imaging, not for treating any condition or disease.
Yes
The "Intended Use / Indications for Use" section explicitly states "The Accuro is intended for diagnostic ultrasound imaging of the human body".
No
The device description explicitly states it is a "hand-held device" and mentions hardware-related standards (IEC60601-1, IEC60601-1-2, IEC60601-2-37, NEMA UD-2, NEMA UD-3) in the performance studies section, indicating it includes hardware components.
Based on the provided information, the Accuro is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use clearly states "diagnostic ultrasound imaging of the human body" for various clinical applications. This involves imaging structures within the body, not analyzing samples outside the body (in vitro).
- Device Description: The device is described as a "hand-held device that features real-time B-mode ultrasound imaging only." This is consistent with an imaging device, not a device that performs tests on biological samples.
- Input Imaging Modality: The input is "Diagnostic ultrasound imaging," which is an in vivo (within the living body) imaging technique.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), reagents, or performing tests on these samples.
IVD devices are specifically designed to examine specimens derived from the human body to provide information for diagnostic purposes. The Accuro's function is to create images of internal structures using ultrasound waves.
N/A
Intended Use / Indications for Use
The Accuro is intended for diagnostic ultrasound imaging of the human body in the following clinical applications: Abdominal, Musculoskeletal (conventional and superficial), Cardiac, Peripheral Vascular, Small Organs (e.g. thyroid, breast), and Pediatrics. A typical examination using the Accuro is guidance of neuraxial anesthesia.
Product codes
IYO, ITX
Device Description
The Accuro is a hand-held device that features real-time B-mode ultrasound imaging only. Additional features include a compact size and a simple user interface.
Mentions image processing
Yes, "BoneEnhance® (image post-processing)" and "SpineNav3D™ (image post-processing)" are mentioned.
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Ultrasound
Anatomical Site
Abdominal, Musculoskeletal (conventional and superficial), Cardiac, Peripheral Vascular, Small Organs (e.g. thyroid, breast), Pediatric. Specific applications include Ophthalmic, Fetal, Intra-operative (Specify), Intra-operative (Neuro), Laparoscopic, Pediatric, Small Organ (thyroid and breast), Neonatal Cephalic, Adult Cephalic, Trans-rectal, Trans-vaginal, Trans-urethral, Trans-esoph. (non-Card), Musculo-skeletal (Conventional), Musculo-skeletal (Superficial), Intravascular, Cardiac Adult, Cardiac Pediatric, Intravascular (Cardiac), Trans-esoph. (Cardiac), Intra-cardiac, Peripheral vessel.
Indicated Patient Age Range
Pediatrics, Neonatal Cephalic, Adult Cephalic (implies adult and neonatal/pediatric range).
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Verification and Validation activities were designed and performed to demonstrate that the Accuro met pre-determined performance specifications. The following standards in conjunction with in-house protocols were used to determine appropriate methods for evaluating the performance of the device: IEC60601-1:2005, IEC60601-1-2:2007, IEC60601-2-37:2007, ISO14971:2007, NEMA UD-2:2004, NEMA UD-3:2004, ISO 10993-1.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 892.1560 Ultrasonic pulsed echo imaging system.
(a)
Identification. An ultrasonic pulsed echo imaging system is a device intended to project a pulsed sound beam into body tissue to determine the depth or location of the tissue interfaces and to measure the duration of an acoustic pulse from the transmitter to the tissue interface and back to the receiver. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.(b)
Classification. Class II (special controls). A biopsy needle guide kit intended for use with an ultrasonic pulsed echo imaging system only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
0
October 20, 2017
Rivanna Medical, LLC % William Mauldin, Ph.D. Chairman, CEO, and Co-founder 107 East Water Street CHARLOTTESVILLE VA 22902
Re: K171594
Trade/Device Name: Accuro Regulation Number: 21 CFR 892.1560 Regulation Name: Ultrasonic pulsed echo imaging system Regulatory Class: II Product Code: IYO, ITX Dated: September 15, 2017 Received: September 21, 2017
Dear Dr. Mauldin:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevicesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely.
Robert Ochs
Robert Ochs, Ph.D. Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K171594
Device Name Accuro
Indications for Use (Describe)
The Accuro is intended for diagnostic ultrasound imaging of the human body in the following clinical applications: Abdominal, Musculoskeletal (conventional and superficial), Cardiac, Peripheral Vascular, Small Organs (e.g. thyroid, breast), and Pediatrics. A typical examination using the Accuro is guidance of neuraxial anesthesia.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
1.3. Indications for Use
1.3.1. 510(k) Indications for Use Form
Diagnostic Ultrasound Indications for Use Form Accuro
Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
| Clinical Application | Mode of Operation | |||||||
|---|---|---|---|---|---|---|---|---|
| General | ||||||||
| (Track 1 | ||||||||
| Only) | Specific | |||||||
| (Track 1 & 3) | B | M | PWD | CWD | Color | |||
| Doppler | Combined | |||||||
| (Specify) | Other* | |||||||
| (Specify) | ||||||||
| Ophthalmic | Ophthalmic | |||||||
| Fetal | ||||||||
| Abdominal | P | 2,3 | ||||||
| Intra-operative (Specify) | ||||||||
| Intra-operative (Neuro) | ||||||||
| Laparoscopic | ||||||||
| Pediatric | N | 2,3,4 | ||||||
| Small Organ[1] (Specify) | N | 2,3 | ||||||
| Neonatal Cephalic | ||||||||
| Fetal | ||||||||
| Imaging & | ||||||||
| Other | Adult Cephalic | |||||||
| Trans-rectal | ||||||||
| Trans-vaginal | ||||||||
| Trans-urethral | ||||||||
| Trans-esoph. (non-Card) | ||||||||
| Musculo-skeletal | ||||||||
| (Conventional) | P | 2,3,4 | ||||||
| Musculo-skeletal | ||||||||
| (Superficial) | P | 2,3,4 | ||||||
| Intravascular | ||||||||
| Other (Specify) | ||||||||
| Cardiac | Cardiac Adult | P | ||||||
| Cardiac Pediatric | ||||||||
| Intravascular (Cardiac) | ||||||||
| Trans-esoph. (Cardiac) | ||||||||
| Intra-cardiac | ||||||||
| Other (Specify) | ||||||||
| Peripheral | ||||||||
| Vessel | Peripheral vessel | P | 2,3 | |||||
| Other (Specify) |
N = new indication; P = previously cleared by FDA in K132736
*Examples of other modes of operation may include Doppler, 3-D Imaging, Harmonic Imaging, Tissue Motion Doppler, and Color Velocity Imaging
Notes:
[2] Image guidance for freehand needle/catheter placement
[3] BoneEnhance® (image post-processing)
[4] SpineNav3D™ (image post-processing)
[1] Small Organ includes thyroid and breast
4
RIVANNA
510 (k) Summary 21 CFR 807.92
Accuro
| General Provisions | Submitter Name:
Submitter Address: | Rivanna Medical, LLC
107 E Water St
Charlottesville, VA 22932 |
|--------------------|---------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|
| | Contact Person: | Will Mauldin, PhD
Chairman, CEO, and Co-founder
(t) 800-645-7508 x701
(e) wmauldin@rivannamedical.com |
| | Date of Preparation: | 09 May 2017 |
| Subject Device | Trade Name: | Accuro |
| | Classification Name: | IYO21 CFR892.1560 Ultrasonic Pulsed Echo
Imaging System
ITX21 CFR892.1570 Diagnostic Ultrasonic
Transducers |
| Predicate Device | Trade Name: | Accuro 3000 Ultrasound Scanner |
| | Classification Name: | IYO21 CFR892.1560 Ultrasonic Pulsed Echo
Imaging System
ITX21 CFR892.1570 Diagnostic Ultrasonic
Transducer |
| | Premarket Notification: K132736, March 11th 2014 | |
| | Manufacturer: | Rivanna Medical, LLC |
| Predicate Device | Trade Name: | Vscan Extend |
| | Classification Name: | IYO21 CFR892.1560 Ultrasonic Pulsed Echo
Imaging System
ITX21 CFR892.1570 Diagnostic Ultrasonic
Transducer |
| | Premarket Notification: K161588, August 31nd 2016 | |
| | Manufacturer: | GE Medical Systems Ultrasound & Primary Care
Diagnostics, LLC |
5
RIVANNA®
Device Description The Accuro is a hand-held device that features real-time B-mode ultrasound imaging only. Additional features include a compact size and a simple user interface. Indications for Use The Accuro is intended for diagnostic ultrasound imaging of the human body in the following clinical applications: Abdominal, Musculoskeletal (conventional and superficial), Cardiac, Peripheral Vascular, Small Organs (e.g. thyroid, breast), and Pediatrics. A typical examination using the Accuro is guidance of neuraxial anesthesia. Technological Characteristics Technological characteristics of the Accuro are equivalent with respect to the basic design and function of the predicate devices. This 510(K) submission expands the Indications for Use of the Accuro 3000 Ultrasound Scanner (K132736). The Accuro has no technologies, features, or indications for use not commonly used in the practice of diagnostic ultrasound. Safety & Performance Tests Verification and Validation activities were designed and performed to demonstrate that the Accuro met pre-determined performance specifications. The following standards in conjunction with in-house protocols were used to determine appropriate methods for evaluating the performance of the device: IEC60601-1:2005, Medical Electrical Equipment - Part 1: General Requirements for Safety and Essential Performance IEC60601-1-2:2007, Medical Electrical Equipment - Part 1-2: General Requirements for Safety -Collateral Standard: Electromagnetic Compatibility Requirements and Tests IEC60601-2-37:2007, Medical Electrical Equipment - Part 2-37: Particular Requirements for the Safety of Ultrasonic Medical Diagnostic and Monitoring Equipment ISO14971:2007, Application of risk management to medical devices, Second edition NEMA UD-2:2004: Acoustic Output Measurement Standard for Diagnostic Ultrasound Equipment NEMA UD-3:2004: Standard for Real-Time Display of Thermal and Mechanical Acoustic Output indices on Diagnostic Ultrasound Equipment ISO 10993-1: Biological Evlauation of Medical Devices- Part 1: Evaluation and Testing Within a Risk Management Process Summary of Substantial Equivalence Based on the indications for use, technological characteristics, and safety and performance testing, the subject Accuro, met
devices.
the minimum requirements that are considered adequate for its intended use and is substantially equivalent in design, principles of operation and indications for use to the predicate
63